Santhera Pharmaceuticals Holding AG

SIX:SANN.SW

9.22 (CHF) • At close September 6, 2024
Bedrijfsnaam Santhera Pharmaceuticals Holding AG
Symbool SANN.SW
Munteenheid CHF
Prijs 9.22
Beurswaarde 108,055,938
Dividendpercentage 0%
52-weken bereik 7.14 - 14.62
Industrie Biotechnology
Sector Healthcare
CEO Dr. Thomas Meier Ph.D.
Website https://www.santhera.com

An error occurred while fetching data.

Over Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy

Vergelijkbare Aandelen

Newron Pharmaceuticals S.p.A. logo

Newron Pharmaceuticals S.p.A.

NWRN.SW

8 CHF

Kuros Biosciences AG logo

Kuros Biosciences AG

KURN.SW

16.78 CHF

Evolva Holding SA logo

Evolva Holding SA

EVE.SW

0.856 CHF

Molecular Partners AG logo

Molecular Partners AG

MOLN.SW

4.77 CHF

Relief Therapeutics Holding AG logo

Relief Therapeutics Holding AG

RLF.SW

2.15 CHF

Financiële Gegevens

Cijfers zijn in miljoenen (CHF)

Cijfers zijn in miljoenen (CHF)